COVID-19 and Influenza Vaccines: Informing Strategies for Mitigation

Strategic Insights -

Vaccine experts have issued a warning about the looming global health challenges posed by the current COVID-19 pandemic and seasonal influenza. New research from the University of North Carolina at Chapel Hill has shed light on the existing strategies for influenza vaccines and how they can inform the development of SARS-CoV-2 vaccines. According to the study, efficacious and safe vaccines remain the frontline tools for mitigating both influenza virus and COVID-19-induced diseases.

Key Takeaways:

  • The COVID-19 pandemic and seasonal influenza represent significant global health challenges, requiring urgent attention and mitigation strategies.
  • Efficacious and safe vaccines are critical for combating both influenza virus and SARS-CoV-2-induced diseases.
  • Research on influenza vaccines has informed the development of SARS-CoV-2 vaccines, highlighting the importance of collaborative efforts between researchers and policymakers.
  • New vaccine platforms and strategies have been developed to address the challenges posed by both viruses.
  • The University of North Carolina at Chapel Hill has been a leading institution in vaccine research and development, with notable contributions to the field of immunology.
  • Adam M. Sandor, Michael S. Sturdivant, and Jenny P. Y. Ting have contributed significantly to the understanding of influenza and SARS-CoV-2 vaccines.
  • The research has been peer-reviewed and published in The Journal of Immunology, providing a comprehensive overview of the current state of vaccine research.

Statistics:

  • The COVID-19 pandemic has resulted in over 185 million reported cases worldwide (WHO, 2021).
  • Seasonal influenza affects an estimated 5-10% of the global population annually (WHO, 2020).
  • The University of North Carolina at Chapel Hill has received funding from NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) and NIH National Cancer Institute (NCI) for vaccine research (NIH, 2021).

Sources:

  • Influenza Virus and Sars-cov-2 Vaccines. The Journal of Immunology, 2021;206(11):2509-2520.
  • University of North Carolina at Chapel Hill. School of Medicine. (2021). Faculty Profile: Jenny P. Y. Ting.
  • NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS). (2021). Overview.
  • NIH National Cancer Institute (NCI). (2021). Overview.